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Abstract Purpose: Cytotoxicity from the anticancer drug
2¢,2¢-difluoro-2¢-deoxycytidine (dFdCyd) has been cor-
related with its incorporation into DNA. However,
cytotoxicity may also result from inhibition of DNA
synthesis, due to either (1) dFdCyd diphosphate-medi-
ated inhibition of ribonucleotide reductase, or (2) direct
inhibition of DNA polymerases by the 5¢-triphosphate
of dFdCyd (dFdCTP). To elucidate the role of DNA
synthesis inhibition in the cytotoxicity of dFdCyd, we
compared dFdCyd to hydroxyurea (HU), a ribonucleo-
tide reductase inhibitor, and aphidicolin, an inhibitor of
DNA polymerases, in the U251 and D54 human glio-
blastoma cell lines. Methods: Sensitivity to dFdCyd,
HU, and aphidicolin were determined using a colony
formation assay. The effects of these drugs on DNA
synthesis were measured by dual parameter flow
cytometry, while the effects on nucleotide pool levels
were analyzed by high-performance liquid chromatog-
raphy.Results: HU and aphidicolin elicited substantially
less cytotoxicity than the multi-log killing with dFdCyd.
When used at equitoxic concentrations (24-h IC50 val-
ues), dFdCyd and HU decreased purine dNTP pools
primarily, but dFdCyd was less effective than HU.
dFdCyd had decreased dATP by about 80% after 4–
12 h, and required 8–24 h to decrease DNA synthesis by
50%. In contrast, HU rapidly depleted dATP by >98%
within 2 h, which resulted in >90% inhibition of DNA
synthesis. Aphidicolin at a concentration similar to its Ki
values for DNA polymerases (1 lM) decreased DNA
synthesis by >70% within 2 h. However, this decreased
cell survival by only 10% (U251 cells) and 40% (D54
cells). Conclusions: These results demonstrate that HU
and aphidicolin produced a more rapid and profound
inhibition of DNA synthesis than dFdCyd, but resulted
in significantly less cytotoxicity. This suggests that
inhibition of DNA synthesis accounted for less than one
log of the multi-log cytotoxicity observed with dFdCyd,
whereas incorporation of dFdCTP into DNA is a more
lethal event.
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Introduction
Many anticancer nucleoside analogs, such as cytosine
arabinoside, cladribine, 2¢,2¢-difluoro-2¢-deoxycytidine
(dFdCyd), and fludarabine, share a common mecha-
nism of cytotoxicity that targets DNA synthesis [35].
After phosphorylation to a 5¢-triphosphate derivative,
nucleoside analogs can interfere with DNA synthesis
by: (1) direct inhibition of DNA polymerases, and (2)
slowing of DNA elongation or chain termination after
insertion into DNA [5, 10, 15, 26, 32, 38, 50]. For some
nucleoside analogs, the incorporation of their 5¢-tri-
phosphates into DNA has been correlated with their
cytotoxicity [21, 23, 41, 51].
In addition to direct effects on DNA synthesis, some
nucleoside derivatives have been shown to inhibit ribo-
nucleotide reductase, but the role this plays in overall
cytotoxicity is not well understood [4, 14, 16, 28, 29, 33,
34, 46, 50]. Ribonucleotide reductase is responsible for
the de novo biosynthesis of deoxyribonucleoside tri-
phosphates (dNTPs) necessary for DNA synthesis in
mammalian cells [22]. Inhibition of ribonucleotide
reductase results in selective decreases in endogenous
dNTPs, depending on the cell line [16, 40, 46]. An
important result of the decrease in endogenous dNTP
pools is that it can lessen competition against the nucle-
otide analog for incorporation into DNA, thus leading to
greater cytotoxicity. This process is known as ‘‘self-
potentiation,’’ and is likely a key factor in the cytotox-
icity of several clinically active nucleoside analogs such as
fludarabine, cladribine, and dFdCyd [6, 14, 17, 36].
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Other anticancer drugs, such as hydroxyurea (HU),
5-fluoro-2¢-deoxyuridine, methotrexate, and N-phos-
phonacetyl-L-aspartate (PALA), elicit cytotoxicity pri-
marily through the alteration of dNTP pools [1, 9, 12,
37]. As expected, these drugs also inhibit DNA syn-
thesis. The role of decreased dNTP pools has become
more interesting with the finding that nucleoside ana-
logs and other drugs that inhibit ribonucleotide
reductase can enhance the effects of ionizing radiation
[13, 27, 39, 45, 46, 47, 48, 49]. The clinically important
drugs HU and dFdCyd have the ability to inhibit
ribonucleotide reductase, either directly as a free radi-
cal scavenger [22], or mechanistically as the 5¢-diphos-
phate derivative of dFdCyd (dFdCDP) [2]. Previous
studies in this and other laboratories have associated
ribonucleotide reductase inhibition with radiosensitiza-
tion by both agents [46, 47]. In contrast, the cytotox-
icity by dFdCyd has been correlated with its
incorporation into DNA [21]. However, incorporation
into DNA and inhibition of ribonucleotide reductase
are interrelated processes, since the level of the 5¢-tri-
phosphate of dFdCyd (dFdCTP) determines the extent
of DNA incorporation, and the amount of dFdCDP is
related to the amount of dFdCTP [15, 21]. This makes
it difficult to distinguish the impact of each pathway
individually on cytotoxicity.
In solid tumor cells, it is particularly important to
evaluate the role of ribonucleotide reductase inhibition
in the action of dFdCyd since non-cytotoxic concen-
trations can produce profound decreases in dATP [25,
46]. Therefore, we compared the effects of dFdCyd on
DNA synthesis with the ribonucleotide reductase
inhibitor HU, and with aphidicolin, which directly
inhibits replicative DNA polymerases without affecting
the dNTP pools [43]. The results demonstrated that
perturbation of dNTP pools or direct polymerase
inhibition contributes primarily to the inhibition of
DNA synthesis without a major effect on cytotoxicity.
A preliminary account of a portion of these results has
been reported in abstract form [30].
Materials and methods
Chemicals
dFdCyd and dFdCTP were synthesized and generously provided
by Eli Lilly and Co. (Indianapolis, Ind.). RNase A was purchased
from Boehringer Mannheim (Indianapolis, Ind.). HU, propidium
iodide, and nucleotide standards were all purchased from Sigma
Chemical Company (St. Louis, Mo.).
Cell culture
The human glioblastoma cell lines U251 and D54 were cultured in
RPMI 1640 medium supplemented with 10% calf serum (GIBCO,
Grand Island, N.Y.) and L-glutamine (Fisher Scientific, Pittsburgh,
Pa.). Cells were maintained in exponential growth in a humidified
atmosphere containing 5% CO2 at 37C.
Cytotoxicity assays
Cytotoxicity was measured using a standard colony formation as-
say. Cell culture flasks (25 cm2) were plated with between 3·105
and 6·105 cells a minimum of 36 h prior to addition of drug.
Exponentially growing cells were incubated with drug for 24 h. At
the conclusion of the drug incubation period, cells were washed
with Dulbecco’s PBS (phosphate-buffered saline), trypsinized, and
counted using a Coulter (Hialeah, Fl.) electronic particle counter.
Approximately 100 viable cells were plated into each 35-mm
diameter well of a six-well culture dish and allowed to grow in the
absence of drug for 10–14 days. At that time, the resulting colonies
were fixed using a methanol/glacial acetic acid solution (3:1 v/v)
and stained with 0.4% crystal violet. Colonies of more than 30 cells
were counted and survival was determined as a fraction of plating
efficiency of untreated control cells.
Analysis of dNTP pools
Cells were incubated with drug for 1–24 h, harvested by trypsini-
zation, and counted. The nucleotides were extracted with ice-cold
0.4 N perchloric acid and neutralized with 10 N potassium hy-
droxyide. The majority of the ribonucleotides were removed from
the deoxyribonucleotides by elution over a boronate affinity col-
umn as described previously [44]. Deoxyribonucleotides were sep-
arated and quantitated by strong anion exchange high-performance
liquid chromatography (HPLC) using a Waters Alliance (Milford,
Mass.) gradient system equipped with a model 996 photodiode
array detector and controlled by Millennium 2010 software. Before
injection, each sample was centrifuged at 16,000 g for 2 min and
acidified to pH 2.8. Samples were then injected onto a 5-lm Par-
tisphere 4.6·250 mm SAX column (Whatman Scientific, Hillsboro,
Ore.) and eluted with a linear gradient of ammonium phosphate
buffer ranging from 0.15 M (pH 2.8) to 0.6 M (pH 2.8–3.8) at a
flow rate of 2 ml/min. Nucleotides were identified and quantitated
by comparison to a known amount of authentic standards using
their characteristic absorbance spectra over the range 200–350 nm.
DNA synthesis
Flow cytometric analysis was performed as previously described
[31]. Briefly, at the conclusion of the drug incubation, cells were
pulse-labeled with 30 lM bromodeoxyuridine (BrdUrd) for
15 min, and then harvested by trypsinization, counted, and washed
with PBS. Cells were then fixed in cold 70% ethanol at a concen-
tration of 1·107 cells/ml, with samples not to exceed a total of
3·107 cells. Fixed cells were stored at 4C for up to 10 days. Within
6 h prior to flow cytometric analysis, fixed cells were washed with
PBS and resuspended in 1 ml PBS containing 0.5 mg/ml RNase A
and incubated for 30 min at 37C. Cells were then washed with
PBS, resuspended in 1 ml 0.1 N hydrochloric acid containing 0.7%
Triton X-100, and incubated for 10 min on ice. This was followed
by another PBS wash, resuspension in 1 ml sterile HPLC grade
water, and incubation at 95C for 15 min. The samples were
immediately transferred to an ice-water bath for an additional
15 min. Cells were then washed with PBS containing 0.5% Tween
20. PBS (100 ll) containing 0.5% Tween 20 and 5% calf serum was
added to each cell pellet followed by the addition of 100 ll anti-
BrdUrd mouse IgG1 antibody (1:100 dilution, BD PharMingen,
San Diego, Calif.) and incubation for 30 min at room temperature.
After centrifugation, 150 ll FITC-conjugated goat anti-mouse IgG
antibody (1:20–35 dilution, Sigma Chemical Company, St. Louis,
Mo.) was added to the pellet, mixed gently, and incubated for
30 min at room temperature. Samples were centrifuged and
resuspended in 0.5 ml 18 lg/ml propidium iodide. Trout erythro-
cyte nuclei (Biosure, Grass Valley, Calif.) were added as an internal
standard. Treated cells were placed in the dark a minimum of
30 min prior to cell cycle analysis using a Coulter EPICS Elite
ESP flow cytometer. Cell cycle data were further analyzed using
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WinMDI software (version 2.8.8) provided by Joseph Trotter of
the Scripps Research Institute. Percent DNA synthesis was deter-
mined by the change in the mean fluorescence intensity of S-phase-
specific BrdUrd incorporation in drug-treated in relation to control
cells. The Quadstat gate to separate BrdUrd-negative cells and




dFdCyd was significantly more potent than HU, with
24-h IC50 values 7,500–120,000 times lower in the U251
and D54 human glioblastoma cell lines (25–80 nM and
0.6–3 mM for dFdCyd and HU, respectively; Fig. 1).
Using concentrations of HU threefold greater than the
24-h IC50 decreased cell survival to about 33% in U251
and about 23% in D54 cells, and a tenfold increase
killed about 1.5 logs of D54 and 76% of U251 cells. In
contrast, increasing the dFdCyd concentration three-
and tenfold over the 24-h IC50 produced 1–3 logs of
cell death in U251 and D54 cells. A similar difference
in potency was also observed between dFdCyd and
HU in HT-29 human colon carcinoma cells (data
not shown).
Effects on purine dNTP pools
In solid tumor cells treated with ribonucleotide
reductase inhibitors, dATP is depleted more rapidly
and to a greater extent compared to the other dNTPs
[25, 46]. Similarly, in the studies presented here both
dFdCyd and HU produced decreases primarily in the
dATP pool. As shown in Table 1, dFdCyd (24-h IC50)
decreased dATP levels within 2 h after drug addition
by <50% in U251 and D54 cells, and dATP con-
tinued to decrease throughout the incubation period
reaching its lowest value by 24 h. Significantly higher
concentrations of dFdCyd (0.4 lM in U251, 4.0 lM in
D54) were required to deplete dATP in both cell lines
to less than 5% of control levels within 4 h (data
not shown). In contrast, the 24-h IC50 doses of HU
Table 1 Perturbation of dNTP pools by inhibitors of ribonucleotide
reductase in U251 and D54 cells. Exponentially growing cells were
treated with either 25 nM or 80 nM dFdCyd (24-h IC50 values) or
0.6 mM or 3 mM HU (24-h IC50 values). Nucleotides were ex-
tracted with perchloric acid, eluted over a boronate affinity column
to reduce ribonucleotides, and separated and quantitated using
HPLC. Data represent the means±SD of one to four determina-
tions. 100% levels of dNTPs in U251 cells are (nmol/107 cells):
dATP 0.171, dGTP 0.099, dCTP 0.412, and dTTP 0.748; and in
D54 cells are dATP 0.341, dGTP 0.105, dCTP 0.479, and dTTP
1.384
Inhibitor Time (h) dATP (%) dGTP (%) dCTP (%) dTTP (%)
U251 D54 U251 D54 U251 D54 U251 D54
dFdCyd 0 100 100 100 100 100 100 100 100
2 53.6±9.6 87.2±7.0 87.4±17.9 118.5±42.2 73.3±12.5 102.9±5.3 74.9±19.7 90.6±14.9
4 19.2±11.1 60.5±11.5 61.4±11.1 75.2±16.3 64.6±1.0 105.7 86.2±17.2 79.8±16.1
12 6.9±5.9 21.6±9.0 54.1±20.9 84.5±10.7 117.6±18.0 88.7±7.0 85.8±15.6 68.6±6.8
24 0.7±0.6 15.0±10.3 44.5±38.8 85.7±25.4 149.4±83.4 130.6±1.1 120.5±61.4 79.8±21.0
HU 0 100 100 100 100 100 100 100 100
2 0.9±1.3 1.7±2.0 23.3±8.4 39.9±16.9 93.3±1.5 74.7±3.1 130.8±40.2 109.4±14.4
4 1.6±1.8 1.7±2.1 24.4±10.0 40.4±14.3 132.3±2.8 84.8±7.7 140.3±5.1 111.7±13.3
12 0.7±0.9 1.2±2.1 25.5±2.7 82.9±23.1 186.7±3.1 142.2±12.4 152.7±35.2 163.1±23.9
24 0.7±0.9 8.4±5.5 38.0±6.7 142.4±43.1 177.4±10.4 261.6±31.5 175.7±31.4 213.8±62.8
Fig. 1A, B Comparison of cytotoxicity of dFdCyd (A) and HU (B)
in human glioblastoma cells. U251 (j) or D54 (d) cells were
treated with drug for 24 h and assayed for clonogenic survival. The
values shown are the means±SE of triplicate determinations from
a single experiment. Experiments were repeated at least three times
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rapidly decreased dATP in both cell lines, achieving
values of less than 2% of control within 2 h of drug
addition in both cell lines. The dGTP pool was also
decreased by both drugs in the two cell lines, although
to a lesser extent compared to dATP. Upon closer
inspection, it was noted that the rate and extent of
dGTP depletion was different between the two agents.
dFdCyd required 4–12 h to deplete dGTP to its lowest
level (54% of control in U251 cells and 75% in D54
cells). In contrast, HU depleted dGTP to 23% of
control in U251 cells and to 40% in D54 cells within
2 h of drug addition. However, by 12 h, dGTP in D54
cells had recovered to 83% of control, and by 24 h
had increased further to 142% of control. In U251
cells, the recovery of dGTP in the presence of HU was
minimal with only 38% of control levels present after
24 h. These data also highlight the fact that, although
IC50 doses were used for both drugs, the effects on the
purine dNTP pools were more marked in the U251
than in the D54 cells.
Effects on pyrimidine dNTP pools
After treatment with either dFdCyd or HU, the
pyrimidine dNTP pools exhibited a markedly different
pattern from the purine dNTP pools. U251 and D54
cells showed little or no changes in dCTP during the
first 4 h after addition of dFdCyd or HU (Table 1).
However, by the end of 24 h, dCTP levels in both cell
lines had increased to 131%–262% of their initial val-
ues. Treatment with dFdCyd only produced marginal
changes in the dTTP pool in the two cell lines during
the 24 h incubation (Table 1). In contrast, HU treat-
ment increased dTTP levels within 2 h, and dTTP
continued to increase achieving final levels of 176%
and 214% of control values in U251 and D54 cells,
respectively, after 24 h. It should be noted that the cell
numbers did not decrease during drug treatment. This
indicated that the increase in pyrimidines observed was
not the result of salvage from lysed cells.
Accumulation of dFdCTP
During a 24-h incubation with equitoxic doses of
dFdCyd (24-h IC50), accumulation of dFdCTP was
similar in the two cell lines (Fig. 2). dFdCTP levels
increased during the first 12 h, when they appeared to
reach a plateau with concentrations of 0.06 nmol/107
cells in U251 cells and 0.05 nmol/107 cells in D54 cells.
We have previously reported that D54 cells incorporate
0.57 nmol/107 cells of dFdCMP and U251 cells incor-
porate 0.40 nmol/107 cells of dFdCMP under these
conditions [31]. Thus, although the IC50 doses for these
cell lines differed by more than threefold, the amount
of dFdCTP and the level of its incorporation into
DNA were similar under equitoxic conditions.
Inhibition of DNA synthesis
In order to determine whether these equitoxic condi-
tions produced similar effects on DNA synthesis, we
compared the ability of each drug to inhibit DNA
synthesis as measured by BrdUrd incorporation and
flow cytometric analysis. S-phase cells were identified
by their ability to incorporate BrdUrd, and the mean
fluorescence intensity of drug-treated cells compared to
control cells yielded the percent control DNA syn-
thesis values. During a 24-h IC50 incubation with
dFdCyd (25 nM and 80 nM for U251 and D54,
respectively), neither cell line showed a decrease in
DNA synthesis within the first 2 h (Fig. 3A). After
4 h, DNA synthesis had decreased to 61% in U251
cells, whereas D54 cells showed no inhibition. DNA
synthesis decreased in both cell lines between 8 and
24 h, at which time it achieved its lowest levels (18%
in U251 cells and 48% in D54 cells). Measurement of
DNA synthesis using [3H]thymidine incorporation
produced similar results (data not shown).
In contrast to dFdCyd, HU (24-h IC50) produced a
more rapid inhibition of DNA synthesis. Within 2 h
of the addition of HU, DNA synthesis was reduced to
<2% of control activity in U251 cells and to <9% of
control in D54 cells (Fig. 3B). In U251 cells, DNA
synthesis was inhibited by >95% throughout the en-
tire 24-h HU exposure. In D54 cells, the level of DNA
synthesis had begun to recover by 8 h and had re-
turned to 30% of control by 24 h. These effects on
DNA synthesis appear to reflect the effects on the
purine dNTP pools, which were depleted faster and to
a greater extent with HU than with dFdCyd.
Fig. 2 Accumulation of dFdCTP in U251 and D54 human
glioblastoma cells. Exponentially growing U251 (j) or D54 (d)
cells were treated with 25 nM and 80 nM dFdCyd (24-h IC50 values
for U251 and D54, respectively). Nucleotides were extracted with
perchloric acid and separated using HPLC. The values shown are
the means±SE from two to four determinations (error bars are




Aphidicolin inhibits replicative DNA polymerases
without any effect on ribonucleotide reductase [43].
Thus, aphidicolin was used to evaluate the effect of
DNA polymerase inhibition alone in the absence of
fraudulent nucleotide incorporation or ribonucleotide
reductase inhibition. Both cell lines were treated with
1 lM aphidicolin for 24 h (U251 IC10, D54 IC40) and
DNA synthesis was measured. DNA synthesis decreased
rapidly in both cell lines. Within 1 h, DNA synthesis
decreased to 40% and 25% of control activity in U251
and D54 cells, respectively (data not shown). DNA
synthesis continued to decrease throughout the first 4 h
with minimum levels of 28% in U251 and 21% in D54
cells (Fig. 3C). By 24 h, U251 cells had recovered to
60% of control DNA synthesis and D54 cells had
recovered to 47% of control.
Discussion
Typically, the ability of a nucleoside analog to be
incorporated into DNA has been associated with its
ability to produce cytotoxicity [21, 23, 35]. Incorpora-
tion of analogs can lead to inhibition of DNA synthesis
by several mechanisms such as chain termination, diffi-
culty extending DNA due to an altered strand confor-
mation, and repetitive attempts to remove the nucleotide
from the DNA strand [10, 20, 21, 26, 32, 33, 35, 38, 42,
50]. However, nucleoside analogs such as dFdCyd,
cladribine, and fludarabine all have additional effects on
DNA synthesis due to their ability to inhibit ribonucle-
otide reductase [6, 16]. Although the effects that these
agents have on dNTP pools and DNA polymerases are
well documented, the relative contribution of these ef-
fects on DNA synthesis and cytotoxicity is not clear. In
the study reported here, we attempted to separate the
effects of dFdCTP accumulation and dNTP depletion on
DNA synthesis and cytotoxicity by comparing dFdCyd
to a pure ribonucleotide reductase inhibitor, HU, and a
pure polymerase inhibitor, aphidicolin.
Both cell lines demonstrated marked differences in
cytotoxicity and dNTP pool depletion with each drug.
At equitoxic concentrations, HU displayed a more rapid
and marked effect on dNTP pools than dFdCyd. The
increased time required by dFdCyd to affect dNTP pools
was most likely due to the requirement of dFdCyd to be
phosphorylated in order to inhibit ribonucleotide
reductase [2, 16]. In fact, the majority of the purine
dNTP depletion occurred during the first 12 h, paral-
leling the time required to achieve peak dFdCTP levels.
Considering that the peak dFdCTP levels in these
studies did not exceed 2 lM (see below), that dFdCDP
levels are typically 5–10% of the dFdCTP concentration
[15], and that 50% inhibition of ribonucleotide reductase
activity in situ requires 0.3 lM dFdCDP [16], the slow
decrease in dNTPs with dFdCyd in these studies is
reasonable.
As found previously in vitro and in vivo [3, 7, 9, 11,
18, 24, 46], inhibition of ribonucleotide reductase in
these studies resulted in a selective decrease in the
purine dNTP pools with no effect on or an increase in
the pyrimidine dNTP pools. Although both dCTP and
dTTP were increased by dFdCyd and HU in these
studies, it is unlikely that these effects played a major
role in the toxicity of these drugs. It has been dem-
onstrated that the increase in dTTP following treat-
ment of 3T6 mouse fibroblasts or V79 Chinese hamster
lung cells with HU is due to an increased uptake of
Fig. 3 Effects of dFdCyd (A), HU (B), and aphidicolin (C) on DNA
synthesis. Exponentially growing U251 cells (gray bars) or D54
cells (black bars) were treated with dFdCyd or HU at their
respective IC50 values, or 1 lM aphidicolin. At the indicated times,
cells were incubated with 30 lM BrdUrd for 15 min prior to
harvest. Cells were prepared as described in Materials and methods
and the BrdUrd content was measured in terms of FITC-
conjugated BrdUrd fluorescence. DNA synthesis inhibition was
determined by the change in mean fluorescence in BrdUrd-
incorporating cells. The data are presented as means±SE of three
determinations (*not done)
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pyrimidine deoxyribonucleosides from the medium [3,
19], which may account for the increase in pyrimidine
dNTP pools observed here. In the studies presented
here, HU produced a greater increase in dCTP and
dTTP than dFdCyd at their IC50 values, and this effect
increased at higher HU (but not dFdCyd) concentra-
tions (data not shown), yet HU was less toxic. Thus,
the increased pyrimidine dNTP pools did not appear to
contribute substantially to cytotoxicity.
The results presented here suggest that the level of
DNA synthesis primarily reflected purine dNTP pool
depletion. The rapid decrease in dATP and dGTP by
HU was associated with an almost complete inhibition
of DNA synthesis in U251 cells and a 90% reduction in
D54 cells. The slower decline in the dATP and dGTP
pools produced by dFdCyd paralleled the slow decrease
in DNA synthesis. Furthermore, the increase in DNA
synthesis observed between 8 and 24 h in D54 cells
treated with HU may be due to the marked recovery of
dGTP levels at 12–24 h.
It was unlikely that dFdCTP had a substantial effect
on DNA polymerases because the peak dFdCTP con-
centrations of 0.06 and 0.05 nmol/107 cells in U251 and
D54 cells, respectively (approximately 1.97 lM and
1.03 lM based on average cell volumes), were 45- to
110-fold lower than the apparent Ki values for either
polymerase a or  in CEM cells as reported by others
[21]. In addition, the levels of dFdCTP in U251 and
D54 cells were seven- and tenfold lower, respectively,
than the endogenous dCTP present at the beginning of
drug treatment, further indicating that this low level of
dFdCTP would be a poor competitor with the higher
levels of dCTP for DNA polymerases. While the
incorporation of dFdCTP into DNA may also con-
tribute to DNA synthesis inhibition, D54 cells incor-
porate more dFdCTP into DNA (0.57 nmol/107 cells)
than U251 cells (0.40 nmol/107 cells) over 24 h under
these conditions [31], yet the level of DNA synthesis at
24 h was more than twofold higher in D54 cells. Taken
together, these results indicate that dNTP perturbation
played a greater role in DNA synthesis inhibition than
the effects of dFdCTP under the conditions utilized
here. Heinemann et al. have shown that the recovery of
DNA synthesis after washout of dFdCyd correlates
with the amount of dFdCTP remaining in CHO cells
[15]. However, dNTP pools, which are directly related
to dFdCDP and, therefore, indirectly related to
dFdCTP, were not measured in that study.
Similar to HU, aphidicolin inhibited DNA synthesis
within 2 h of treatment, although the amount of DNA
synthesis inhibition was less than that produced by the
depletion of dNTPs in response to HU. The degree of
inhibition was reasonable considering that the concen-
tration of aphidicolin used was in the reported range of
apparent Ki values for DNA polymerases a, d, and  of
0.2–2.2 lM [8, 43]. The relative level of aphidicolin
with respect to the Ki values for DNA polymerases was
greater than the comparative values for dFdCTP, yet
aphidicolin produced a similar amount of inhibition as
a 12–16 h exposure to dFdCyd. This suggests that
DNA synthesis inhibition with dFdCyd is the result of
the combined effects of dNTP pool depletion and
dFdCTP incorporated into DNA, rather than direct
inhibition of polymerases by dFdCTP. Despite a more
rapid inhibition of DNA synthesis compared to
dFdCyd, aphidicolin was only mildly cytotoxic, further
supporting the conclusion that DNA synthesis inhibi-
tion alone is not a highly cytotoxic event in these cells.
Direct polymerase inhibition produced by aphidic-
olin and the rapid depletion of dATP and dGTP pro-
duced by HU resulted in a profound inhibition of
DNA synthesis, yet these drugs produced a maximum
of approximately one-log of cell death at high con-
centrations. dFdCyd has the ability to produce dNTP
depletion as well as direct DNA synthesis inhibition,
but at equitoxic concentrations had a lesser effect on
DNA synthesis compared to aphidicolin and HU.
However, dFdCyd was significantly more cytotoxic
than either of the other two drugs. These results taken
together suggest that a decrease in dNTP pools and the
resulting decrease in DNA synthesis contributed less
than one-log of cell death with dFdCyd, and the
remaining multiple logs of cell death resulted from the
incorporation of dFdCTP into DNA.
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